Indivior Pharmaceuticals (INDV) Revenue (2024 - 2026)

Indivior Pharmaceuticals' Revenue history runs 3 years deep, the most recent figure standing at $317.0 million for Q1 2026.

• In Q1 2026, Revenue rose 19.17% year-over-year to $317.0 million; the TTM figure through Mar 2026 stood at $1.3 billion (up 10.25% YoY), while the FY2025 annual figure was $1.2 billion, up 4.29% from the prior year.
• Revenue was $317.0 million for Q1 2026 at Indivior Pharmaceuticals, down from $358.0 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $358.0 million in Q4 2025 to a low of $266.0 million in Q1 2025.
• Historically, Revenue has averaged $305.1 million across 3 years, with a median of $302.0 million in 2025.
• Biggest YoY gain for Revenue was 19.73% in 2025; the steepest drop was 6.34% in 2025.
• A 3-year view of Revenue shows it stood at $299.0 million in 2024, then gained by 19.73% to $358.0 million in 2025, then retreated by 11.45% to $317.0 million in 2026.
• The last three Revenue figures came in at $317.0 million (Q1 2026), $358.0 million (Q4 2025), and $314.0 million (Q3 2025), per Business Quant data.